Published on 12/12/2017 in the Prospect News Structured Products Daily.
New Issue: Credit Suisse sells $441,000 contingent coupon callable notes on biotech ETF, S&P
By Marisa Wong
Morgantown, W.Va., Dec. 12 – Credit Suisse AG, London Branch priced $441,000 of contingent coupon callable yield notes due Dec. 7, 2020 linked to the lowest performing of the S&P 500 index and the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.
The notes will pay a quarterly coupon at an annualized rate of 9% if each asset closes at or above its barrier level, 60% of its initial level, on a quarterly observation date.
The notes are callable at par on any coupon payment date after June 5, 2018.
The payout at maturity will be par unless either asset finishes below its 60% knock-in level, in which case investors will be exposed to any losses of the lesser-performing asset.
Credit Suisse Securities (USA) LLC is the agent.
| Issuer: | Credit Suisse AG, London Branch
|
| Issue: | Contingent coupon callable yield notes
|
| Underlying assets: | S&P 500 index and SPDR S&P Biotech exchange-traded fund
|
| Amount: | $441,000
|
| Maturity: | Dec. 7, 2020
|
| Coupon: | 9% per year, payable quarterly if each asset closes at or above its barrier level on quarterly observation date
|
| Price: | Par
|
| Payout at maturity: | Par unless either asset finishes below its knock-in level, in which case investors will be exposed to any losses of lesser-performing asset
|
| Call option: | At par on any coupon payment date after June 5, 2018
|
| Initial levels: | 2,647.58 for index, $83.19 for ETF
|
| Barrier/knock-in levels: | 1,588.548 for index, $49.914 for ETF; 60% of initial levels
|
| Pricing date: | Nov. 30
|
| Settlement date: | Dec. 5
|
| Agent: | Credit Suisse Securities (USA) LLC
|
| Fees: | 0.95%
|
| Cusip: | 22550BMN0
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
